Identifying predictive biomarkers of CIMAvaxEGF success in non–small cell lung cancer patients

[1] Rodriguez PC(2016)A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung Cancer patients Clin Cancer Res 22 3782-3790

[2] Popa X(2015)CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer Expert Rev Vaccines 14 1303-1311

[3] Martinez O(2008)Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J Clin Oncol 26 1452-1458

[4] Mendoza S(2008)Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine Clin Cancer Res 14 840-846

[5] Santiesteban E(2003)Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Ann Oncol 14 461-466

[6] Crespo T(2018)Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer Semin Oncol 45 52-57

[7] Amador RM(2016)Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients Cancer Immunol Immun 65 37-45

[8] Fleytas R(2015)Validating predictors of therapeutic success: a causal inference approach Stat Model 15 619-636

[9] Acosta SC(2006)Dichotomizing continuous predictors in multiple regression: a bad idea Stat Med 25 127-141

[10] Otero Y(2019)The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy Cancer 125 127-134

[1] Rodriguez PC(2016)A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung Cancer patients Clin Cancer Res 22 3782-3790

[2] Popa X(2015)CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer Expert Rev Vaccines 14 1303-1311

[3] Martinez O(2008)Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J Clin Oncol 26 1452-1458

[4] Mendoza S(2008)Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine Clin Cancer Res 14 840-846

[5] Santiesteban E(2003)Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Ann Oncol 14 461-466

[6] Crespo T(2018)Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer Semin Oncol 45 52-57

[7] Amador RM(2016)Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients Cancer Immunol Immun 65 37-45

[8] Fleytas R(2015)Validating predictors of therapeutic success: a causal inference approach Stat Model 15 619-636

[9] Acosta SC(2006)Dichotomizing continuous predictors in multiple regression: a bad idea Stat Med 25 127-141

[10] Otero Y(2019)The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy Cancer 125 127-134